{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:40:45Z","timestamp":1770223245191,"version":"3.49.0"},"reference-count":105,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T00:00:00Z","timestamp":1507852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vet Comparative Oncology"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:p>Cytotoxic drugs encapsulated into liposomes were originally designed to increase the anticancer response, while minimizing off\u2010target adverse effects. The first liposomal chemotherapeutic drug was approved for use in humans more than 20\u2009years ago, and the first publication regarding its use in a canine cancer patient was published shortly thereafter. Regardless, no general application for liposomal cytotoxic drugs has been established in veterinary oncology till now. Due to the popularity of canines as experimental models for pharmacokinetic analyses and toxicity studies, multiple publications exist describing various liposomal drugs in healthy dogs. Also, some evidence for its use in veterinary cancer patients exists, especially in canine lymphoma, canine splenic hemangiosarcoma and feline soft tissue sarcoma, however, the results have not been overwhelming. Reasons for this may be related to inherent issues with the enhanced permeability and retention effect, the tumour phenomenon which liposomal drugs exploit. This effect seems very heterogeneously distributed in the tumour. Also, it is potentially not as ubiquitously occurring as once thought, and it may prove important to select patients for liposomal therapy on an individual, non\u2010histology\u2010oriented, basis. Concurrently, new developments with active\u2010release modified liposomes in experimental models and humans will likely be relevant for veterinary patients as well, and holds the potential to improve the therapeutic response. It, however, does not resolve the other challenges that liposomal chemotherapy faces, and more work still needs to be done to determine which veterinary patients may benefit the most from liposomal chemotherapy.<\/jats:p>","DOI":"10.1111\/vco.12342","type":"journal-article","created":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T08:53:56Z","timestamp":1507884836000},"source":"Crossref","is-referenced-by-count":10,"title":["Liposome\u2010encapsulated chemotherapy: Current evidence for its use in companion animals"],"prefix":"10.1111","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0285-024X","authenticated-orcid":false,"given":"B.","family":"B\u00f8rresen","sequence":"first","affiliation":[{"name":"Department of Veterinary Clinical Sciences University of Copenhagen Frederiksberg C Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. E.","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Sciences University of Copenhagen Frederiksberg C Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kj\u00e6r","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Sciences University of Copenhagen Frederiksberg C Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. L.","family":"Andresen","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Sciences University of Copenhagen Frederiksberg C Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. T.","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Sciences University of Copenhagen Frederiksberg C Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,10,13]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2010.03.011"},{"key":"e_1_2_10_3_1","doi-asserted-by":"crossref","unstructured":"Perez\u2010SolerR LautersztainJ StephensLC WrightK KhokharAR. Preclinical toxicity and pharmacology of liposome\u2010entrapped cis\u2010bis\u2010neodecanoato\u2010trans\u2010R R\u20101 2\u2010diaminocyclohexane platinum(II).Cancer Chemother Pharmacol.1989;24(1):1\u20108.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/2720887. Accessed September 17 2015.","DOI":"10.1007\/BF00254097"},{"key":"e_1_2_10_4_1","doi-asserted-by":"crossref","unstructured":"KisseberthWC MacEwenEG HelfandSC VailDM LondonCL KellerE. Response to liposome\u2010encapsulated doxorubicin (TLC D\u201099) in a dog with myeloma.J Vet Intern Med.1995;9(6):425\u2010428.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/855849. Accessed September 18 2015.","DOI":"10.1111\/j.1939-1676.1995.tb03304.x"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-016-1958-5"},{"issue":"12","key":"e_1_2_10_6_1","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura Y","year":"1986","journal-title":"Cancer Res"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197111182852108"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.37263"},{"key":"e_1_2_10_9_1","unstructured":"YuanF DellianM FukumuraD et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.Cancer Res.1995;55(17):3752\u20103756.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7641188. Accessed April 7 2017."},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2012.09.003"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1023565227808"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S68861"},{"key":"e_1_2_10_13_1","doi-asserted-by":"crossref","unstructured":"IshiharaH.Current status and prospects of polyethyleneglycol\u2010modified medicines.Biol Pharm Bull.2013;36(6):883\u2010888.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23727910. Accessed June 19 2014.","DOI":"10.1248\/bpb.b13-00087"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2012.03.020"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-013-0070-1"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2008.n.001"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5829.2011.00314.x"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.12596"},{"key":"e_1_2_10_19_1","unstructured":"GabizonAA BarenholzY BialerM. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol\u2010derivatized phospholipid: pharmacokinetic studies in rodents and dogs.Pharm Res.1993;10(5):703\u2010708.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8321835. Accessed September 17 2015."},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2012.07.049"},{"key":"e_1_2_10_21_1","unstructured":"HermanEH RahmanA FerransVJ VickJA ScheinPS. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation.Cancer Res.1983;43(11):5427\u20105432.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/6616474. Accessed June 19 2014."},{"key":"e_1_2_10_22_1","unstructured":"KanterPM BullardGA PilkiewiczFG MayerLD CullisPR PavelicZP. Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D\u201099): comparison with doxorubicin and empty liposomes in mice and dogs.In Vivo.1993;7(1):85\u201095.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8504212. Accessed September 17 2015."},{"key":"e_1_2_10_23_1","doi-asserted-by":"crossref","unstructured":"WorkingPK NewmanMS SullivanT YarringtonJ. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long\u2010circulating pegylated liposomes.J Pharmacol Exp Ther.1999;289(2):1128\u20101133.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10215696. Accessed September 17 2015.","DOI":"10.1016\/S0022-3565(24)38244-8"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/096032719901800103"},{"key":"e_1_2_10_25_1","unstructured":"KanterPM KlaichG BullardGA KingJM PavelicZP. Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D\u201099) given intraperitoneally to dogs.In Vivo.1994;8(6):975\u2010982.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7772749. Accessed September 17 2015."},{"key":"e_1_2_10_26_1","doi-asserted-by":"crossref","unstructured":"KiyokawaH IgawaY MuraishiO KatsuyamaY IizukaK NishizawaO. Distribution of doxorubicin in the bladder wall and regional lymph nodes after bladder submucosal injection of liposomal doxorubicin in the dog.J Urol.1999;161(2):665\u2010667.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9915479. Accessed June 19 2014.","DOI":"10.1016\/S0022-5347(01)61991-8"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2352031856"},{"key":"e_1_2_10_28_1","doi-asserted-by":"crossref","unstructured":"KanterPM KlaichGM BullardGA KingJM BallyMB MayerLD. Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice rats and dogs.Anticancer Drugs.1994;5(5):579\u2010590.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7858291. Accessed September 17 2015.","DOI":"10.1097\/00001813-199410000-00010"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2369-5"},{"key":"e_1_2_10_30_1","doi-asserted-by":"crossref","unstructured":"MarrAK KurzmanID VailDM. Preclinical evaluation of a liposome\u2010encapsulated formulation of cisplatin in clinically normal dogs.Am J Vet Res.2004;65(11):1474\u20101478.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15566083. Accessed June 19 2014.","DOI":"10.2460\/ajvr.2004.65.1474"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.2011.01422.x"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2013.01.012"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23254"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1349126"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.2010.01184.x"},{"key":"e_1_2_10_36_1","unstructured":"PalA KhanS WangY\u2010F et al. Preclinical safety pharmacokinetics and antitumor efficacy profile of liposome\u2010entrapped SN\u201038 formulation.Anticancer Res.2005;25(1A):331\u2010341.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15816556. Accessed April 19 2014."},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-016-0484-4"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.3171\/JNS\/2008\/108\/5\/0989"},{"key":"e_1_2_10_39_1","doi-asserted-by":"crossref","unstructured":"ThammDH VailDM. Preclinical evaluation of a sterically stabilized liposome\u2010encapsulated cisplatin in clinically normal cats.Am J Vet Res.1998;59(3):286\u2010289.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9522946. Accessed June 19 2014.","DOI":"10.2460\/ajvr.1998.59.03.286"},{"key":"e_1_2_10_40_1","doi-asserted-by":"crossref","unstructured":"FoxLE ToshachK Calderwood\u2010MaysM et al. Evaluation of toxicosis of liposome\u2010encapsulated cis\u2010bis\u2010neodecanoato\u2010trans\u2010R R\u20101 2\u2010diaminocyclohexane platinum (II) in clinically normal cats.Am J Vet Res.1999;60(2):257\u2010263.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10048562. Accessed June 19 2014.","DOI":"10.2460\/ajvr.1999.60.02.257"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl477"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5829.2007.00142.x"},{"key":"e_1_2_10_43_1","unstructured":"NCI Comparative Oncology Program web page.https:\/\/ccrod.cancer.gov\/confluence\/display\/CCRCOPWeb\/Closed+Clincal+Trials. Accessed February 20 2017."},{"key":"e_1_2_10_44_1","doi-asserted-by":"crossref","unstructured":"SpencerCM FauldsD. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.Drugs.1994;48(5):794\u2010847.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7530632. Accessed January 9 2017.","DOI":"10.2165\/00003495-199448050-00009"},{"key":"e_1_2_10_45_1","doi-asserted-by":"crossref","unstructured":"LorenzW SchmalA SchultH et al. Histamine release and hypotensive reactions in dogs by solubilizing agents and fatty acids: analysis of various components in cremophor El and development of a compound with reduced toxicity.Agents Actions.1982;12(1\u20132):64\u201080.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/6177219. Accessed November 11 2016.","DOI":"10.1007\/BF01965109"},{"key":"e_1_2_10_46_1","unstructured":"RivoryLP HaazMC CanalP LokiecF ArmandJP RobertJ. Pharmacokinetic interrelationships of irinotecan (CPT\u201011) and its three major plasma metabolites in patients enrolled in phase I\/II trials.Clin Cancer Res.1997;3(8):1261\u20101266.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9815808. Accessed January 29 2017."},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.10.2688"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050591"},{"key":"e_1_2_10_49_1","unstructured":"VailDM ChunR ThammDH GarrettLD CooleyAJ ObradovichJE. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized double\u2010blind clinical trial using a canine model.Clin Cancer Res.1998;4(6):1567\u20101571.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9626479. Accessed June 19 2014."},{"key":"e_1_2_10_50_1","doi-asserted-by":"crossref","unstructured":"SorenmoK SamlukM CliffordC et al. Clinical and pharmacokinetic characteristics of intracavitary administration of pegylated liposomal encapsulated doxorubicin in dogs with splenic hemangiosarcoma.J Vet Intern Med.2007;21(6):1347\u20101354.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18196746. Accessed June 19 2014.","DOI":"10.1111\/j.1939-1676.2007.tb01958.x"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5829.2011.00266.x"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0226"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-002-0469-8"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq046"},{"key":"e_1_2_10_55_1","doi-asserted-by":"crossref","unstructured":"FoxLE RosenthalRC KingRR et al. Use of cis\u2010bis\u2010neodecanoato\u2010trans\u2010R R\u20101 2\u2010diaminocyclohexane platinum (II) a liposomal cisplatin analogue in cats with oral squamous cell carcinoma.Am J Vet Res.2000;61(7):791\u2010795.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10895902. Accessed June 19 2014.","DOI":"10.2460\/ajvr.2000.61.791"},{"key":"e_1_2_10_56_1","doi-asserted-by":"crossref","unstructured":"PoirierVJ ThammDH KurzmanID et al. Liposome\u2010encapsulated doxorubicin (Doxil) and doxorubicin in the treatment of vaccine\u2010associated sarcoma in cats.J Vet Intern Med.2002;16(6):726\u2010731.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12465772. Accessed June 19 2014.","DOI":"10.1111\/j.1939-1676.2002.tb02415.x"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1740-8261.2009.01661.x"},{"issue":"2","key":"e_1_2_10_58_1","first-page":"1","article-title":"A pilot trial of doxorubicin containing phosphatidyldiglycerol based thermosensitive liposomes in spontaneous feline soft tissue sarcoma","volume":"33","author":"Zimmermann K","year":"2016","journal-title":"Int J Hyperthermia"},{"key":"e_1_2_10_59_1","doi-asserted-by":"crossref","unstructured":"FabianCJ MolinaR SlavikM DahlbergS GiriS StephensR. Pyridoxine therapy for palmar\u2010plantar erythrodysesthesia associated with continuous 5\u2010fluorouracil infusion.Invest New Drugs.1990;8(1):57\u201063.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/2345070. Accessed November 30 2016.","DOI":"10.1007\/BF00216925"},{"key":"e_1_2_10_60_1","doi-asserted-by":"crossref","unstructured":"VukeljaSJ BakerWJ BurrisHA KeelingJH Von HoffD. Pyridoxine therapy for palmar\u2010plantar erythrodysesthesia associated with taxotere.J Natl Cancer Inst.1993;85(17):1432\u20101433.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8102408. Accessed November 30 2016.","DOI":"10.1093\/jnci\/85.17.1432"},{"key":"e_1_2_10_61_1","doi-asserted-by":"crossref","unstructured":"StrawRC WithrowSJ RichterSL et al. Amputation and cisplatin for treatment of canine osteosarcoma.J Vet Intern Med.1991;5(4):205\u2010210.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1941754. Accessed May 2 2017.","DOI":"10.1111\/j.1939-1676.1991.tb00950.x"},{"key":"e_1_2_10_62_1","doi-asserted-by":"crossref","unstructured":"ThompsonJP FugentMJ. Evaluation of survival times after limb amputation with and without subsequent administration of cisplatin for treatment of appendicular osteosarcoma in dogs: 30 cases (1979\u20131990).J Am Vet Med Assoc.1992;200(4):531\u2010533.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1559895. Accessed May 2 2017.","DOI":"10.2460\/javma.1992.200.04.531"},{"key":"e_1_2_10_63_1","first-page":"463","volume-title":"Withrow and MacEwen's Small Animal Clinical Oncology","author":"Ehrhart NP","year":"2012"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2014.924399"},{"key":"e_1_2_10_65_1","doi-asserted-by":"crossref","unstructured":"MacEwenEG KurzmanID RosenthalRC et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome\u2010encapsulated muramyl tripeptide.J Natl Cancer Inst.1989;81(12):935\u2010938.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/2733037. Accessed November 29 2016.","DOI":"10.1093\/jnci\/81.12.935"},{"key":"e_1_2_10_66_1","doi-asserted-by":"crossref","unstructured":"KleinermanES GanoJB JohnstonDA BenjaminRS JaffeN. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.Am J Clin Oncol.1995;18(2):93\u201099.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7900714. Accessed September 20 2015.","DOI":"10.1097\/00000421-199504000-00001"},{"key":"e_1_2_10_67_1","unstructured":"KurzmanID MacEwenEG RosenthalRC et al. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome\u2010encapsulated muramyl tripeptide and cisplatin.Clin Cancer Res.1995;1(12):1595\u20101601.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9815961. Accessed June 19 2014."},{"key":"e_1_2_10_68_1","unstructured":"MacEwenEG KurzmanID VailDM et al. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery liposome\u2010encapsulated muramyl tripeptide and granulocyte macrophage colony\u2010stimulating factor.Clin Cancer Res.1999;5(12):4249\u20104258.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10632367. Accessed September 17 2015."},{"key":"e_1_2_10_69_1","unstructured":"TeskeE RuttemanGR. Liposome\u2010enhanced tumour therapy in canine mammary gland tumours.Tijdschr Diergeneeskd1993;118 suppl:32S\u201033S.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8480312. Accessed June 19 2014."},{"key":"e_1_2_10_70_1","unstructured":"VailDM MacEwenEG KurzmanID et al. Liposome\u2010encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi\u2010institutional clinical trial.Clin Cancer Res.1995;1(10):1165\u20131170.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9815908. Accessed September 17 2015."},{"key":"e_1_2_10_71_1","doi-asserted-by":"crossref","unstructured":"FoxLE MacEwenEG KurzmanID et al. Liposome\u2010encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma \u2013 a multicenter randomized double\u2010blind study.Cancer Biother.1995;10(2):125\u2010130.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7663571. Accessed March 28 2017.","DOI":"10.1089\/cbr.1995.10.125"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.2165\/11204910-000000000-00000"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2005.16.937"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700895"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-009-0763-y"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2005.07.023"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.208.2.9680581"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00595.2003"},{"key":"e_1_2_10_79_1","first-page":"432","volume-title":"Withrow and MacEwen's Small Animal Clinical Oncology","author":"Withrow SJ","year":"2012"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.5326\/JAAHA\u2010MS\u20105929"},{"key":"e_1_2_10_81_1","doi-asserted-by":"crossref","unstructured":"MutsaersAJ GlickmanNW DeNicolaDB et al. Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs.J Am Vet Med Assoc.2002;220(12):1813\u20101817.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12092954. Accessed January 29 2017.","DOI":"10.2460\/javma.2002.220.1813"},{"issue":"2","key":"e_1_2_10_82_1","first-page":"243","article-title":"Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes","volume":"7","author":"Harrington KJ","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_10_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91188-G"},{"key":"e_1_2_10_84_1","doi-asserted-by":"crossref","unstructured":"KhalifaA DoddsD RamplingR PatersonJ MurrayT. Liposomal distribution in malignant glioma: possibilities for therapy.Nucl Med Commun.1997;18(1):17\u201023.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9061696. Accessed December 6 2016.","DOI":"10.1097\/00006231-199701000-00005"},{"key":"e_1_2_10_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)92379-V"},{"key":"e_1_2_10_86_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5b01324"},{"key":"e_1_2_10_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2010.139"},{"key":"e_1_2_10_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2011.04.006"},{"key":"e_1_2_10_89_1","doi-asserted-by":"crossref","unstructured":"HarringtonKJ LewanskiCR NorthcoteAD et al. Phase I\u2010II study of pegylated liposomal cisplatin (SPI\u2010077) in patients with inoperable head and neck cancer.Ann Oncol.2001;12(4):493\u2010496.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11398881. Accessed February 6 2017.","DOI":"10.1023\/A:1011199028318"},{"key":"e_1_2_10_90_1","doi-asserted-by":"crossref","unstructured":"KimES LuC KhuriFR et al. A phase II study of STEALTH cisplatin (SPI\u201077) in patients with advanced non\u2010small cell lung cancer.Lung Cancer.2001;34(3):427\u2010432.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11714540. Accessed February 6 2017.","DOI":"10.1016\/S0169-5002(01)00278-1"},{"key":"e_1_2_10_91_1","doi-asserted-by":"crossref","unstructured":"BandakS GorenD HorowitzA TzemachD GabizonA. Pharmacological studies of cisplatin encapsulated in long\u2010circulating liposomes in mouse tumor models.Anticancer Drugs.1999;10(10):911\u2010920.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10630359. Accessed February 6 2017.","DOI":"10.1097\/00001813-199911000-00007"},{"key":"e_1_2_10_92_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-003-0719-4"},{"key":"e_1_2_10_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2004.12.001"},{"key":"e_1_2_10_94_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2013.805742"},{"key":"e_1_2_10_95_1","doi-asserted-by":"crossref","unstructured":"AndresenTL JensenSS KaasgaardT J\u00f8rgensenK. Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2.Curr Drug Deliv.2005;2(4):353\u2013362.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16305438. Accessed February 6 2017.","DOI":"10.2174\/156720105774370203"},{"key":"e_1_2_10_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2013.11.009"},{"key":"e_1_2_10_97_1","doi-asserted-by":"publisher","DOI":"10.1021\/bc9000646"},{"key":"e_1_2_10_98_1","doi-asserted-by":"publisher","DOI":"10.3109\/09687688.2010.515950"},{"key":"e_1_2_10_99_1","doi-asserted-by":"crossref","unstructured":"MoussaHG MartinsAM HusseiniGA. Review on triggered liposomal drug delivery with a focus on ultrasound.Curr Cancer Drug Targets.2015;15(4):282\u2010313.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25760762. Accessed February 6 2017.","DOI":"10.2174\/1568009615666150311100610"},{"key":"e_1_2_10_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2012.10.008"},{"key":"e_1_2_10_101_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2014.866650"},{"key":"e_1_2_10_102_1","doi-asserted-by":"crossref","unstructured":"LanaSE OgilvieGK HansenRA PowersBE DernellWS WithrowSJ. Identification of matrix metalloproteinases in canine neoplastic tissue.Am J Vet Res.2000;61(2):111\u2010114.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10685678. Accessed February 6 2017.","DOI":"10.2460\/ajvr.2000.61.111"},{"key":"e_1_2_10_103_1","unstructured":"GebhardC Fuchs\u2010BaumgartingerA Razzazi\u2010FazeliE MillerI WalterI. Distribution and activity levels of matrix metalloproteinase 2 and 9 in canine and feline osteosarcoma.Can J Vet Res.2016;80(1):66\u201073.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26733734. Accessed February 6 2017."},{"issue":"2","key":"e_1_2_10_104_1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0022-3565(24)29419-2","article-title":"Factors affecting the accelerated blood clearance of polyethylene glycol\u2010liposomes upon repeated injection","volume":"298","author":"Laverman P","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_10_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2013.07.026"},{"key":"e_1_2_10_106_1","doi-asserted-by":"publisher","DOI":"10.2165\/11207510-000000000-00000"}],"container-title":["Veterinary and Comparative Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fvco.12342","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vco.12342","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T13:19:55Z","timestamp":1750943995000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vco.12342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,13]]},"references-count":105,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/vco.12342"],"URL":"https:\/\/doi.org\/10.1111\/vco.12342","archive":["Portico"],"relation":{},"ISSN":["1476-5810","1476-5829"],"issn-type":[{"value":"1476-5810","type":"print"},{"value":"1476-5829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,13]]}}}